Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 35% Improvement Relative Risk c19hcq.org AlQadheeb et al. HCQ for COVID-19 ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 848 patients in Saudi Arabia (March 2020 - August 2021) Lower mortality with HCQ (p=0.00011) AlQadheeb et al., Clinical Infection in Practice, doi:10.1016/j.clinpr.2023.100229 Favors HCQ Favors control

Impact of common comorbidities on antimicrobial consumption and mortality amongst critically ill COVID-19 patients: A retrospective two center study in Saudi Arabia

AlQadheeb et al., Clinical Infection in Practice, doi:10.1016/j.clinpr.2023.100229
AlQadheeb et al., Impact of common comorbidities on antimicrobial consumption and mortality amongst critically ill COVID-19.., Clinical Infection in Practice, doi:10.1016/j.clinpr.2023.100229
May 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 848 ICU patients in Saudi Arabia, showing lower mortality with HCQ in unadjusted results.
risk of death, 34.8% lower, RR 0.65, p < 0.001, treatment 37 of 92 (40.2%), control 466 of 756 (61.6%), NNT 4.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
AlQadheeb et al., 10 May 2023, retrospective, Saudi Arabia, peer-reviewed, mean age 55.8, 9 authors, study period March 2020 - August 2021.
Contact: nada.qadheeb@kfsh.med.sa, nalqadheeb@moh.gov.sa.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Clinical Infection in Practice 19 (2023) 100229 Contents lists available at ScienceDirect Clinical Infection in Practice journal homepage: www.sciencedirect.com/journal/clinical-infection-in-practice Practical clinical reviews Impact of common comorbidities on antimicrobial consumption and mortality amongst critically ill COVID-19 patients: A retrospective two center study in Saudi Arabia Nada AlQadheeb a, *, Hanine AlMubayedh b, Sarah AlBadrani b, Abdul Salam c, Mukhtar AlOmar a, Ahmed AlAswad d, Mohammed AlMualim d, Zahra AlQamariat e, Rasheed AlHubail f a Pharmacy Department, King Fahad Specialist Hospital, Eastern Province, Saudi Arabia College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Eastern Province, Saudi Arabia c Department of Biostatistics and Epidemiology, King Fahad Specialist Hospital, Eastern Province, Saudi Arabia d Critical Care Department, Qatif Central Hospital, Eastern Province, Saudi Arabia e Pharmacy Department, Dammam Medical Complex, Eastern Province, Saudi Arabia f Critical Care Department, Dammam Medical Complex, Eastern Province, Saudi Arabia b A R T I C L E I N F O A B S T R A C T Keywords: Mortality COVID-19 Comorbidities Intensive care unit Saudi Arabia Objectives: To determine the association between common comorbidities, ICU mortality and antimicrobial con­ sumption among critically ill COVID 19 patients in Saudi Arabia. Methods: A retrospective observational study of patients admitted to the ICU from March 1st, 2020, through August 31st, 2021. We excluded patients who stayed <24 h in the ICU and with no confirmed COVID-19 PCR testing. Results: Of the 976 screened ICU patients, 848 were included. While there was no difference in mortality between patients with and without comorbidities, those with at least one comorbidity had a higher severity of illness (p = 0.013). Compared to survivors, non-survivors were more likely to require mechanical ventilation and vasopressor support (P < 0.001). Almost all patients received at least one antimicrobial therapy. Predictors independently associated with ICU mortality were: older age (adjusted odds ratio [AOR], 1.03; 95% confidence interval [CI], 1.01–1.04), vancomycin use (AOR, 2.69; 95% [CI], 1.65–4.37), linezolid use (AOR, 2.65; 95% [CI], 1.65–4.04), sepsis or septic shock (AOR, 6.39; 95% [CI], 3.68–11.08), Acute Kidney Injury (AKI) (AOR, 2.51; 95% [CI], 1.61–3.92) and Acute Respiratory Distress Syndrome (ARDS) (AOR, 2.03; 95% [CI], 1.61–3.92). Conclusion: Older age, vancomycin and linezolid use, sepsis/septic shock, AKI, and ARDS were negative prog­ nostic factors in critically ill COVID-19 patients. More studies are needed to evaluate the outcomes of survived critically ill patients in relation to their vaccination status.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit